Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
The paper suggests that semaglutide represents a significant advancement in obesity treatment, but specific outcomes are not detailed.
Where it sits
this study against the rest of the cagrilintide (am833) corpusSummary and findings
This paper discusses the implications of once-weekly 2.4 mg semaglutide for weight management in obesity, highlighting its effectiveness compared to previous treatments. It emphasizes the need for sustained weight loss and the potential of newer drugs like cagrilintide. No specific numeric outcomes are reported in the abstract.
Abstract
The treatment of obesity can no longer be reduced to a simplistic view of weight loss. Metabolic adaptation leads to systematic weight regain following weight-loss efforts, and new obesity treatments should therefore aim to induce long-standing double-digit weight loss, and thus improve and even reverse obesity-associated comorbidities such as type 2 diabetes. Until now, only metabolic surgery has been able to achieve such a goal, but this invasive procedure cannot be offered on a large scale. Among the alternatives, lifestyle interventions and drug therapies have often been disappointing. The recent availability of once-weekly subcutaneous 2.4 mg semaglutide (a glucagon-like peptide-1 receptor agonist; Wegovy™ Novo Nordisk A/S, Bagsværd, Denmark) has changed the scene, and semaglutide is considered a 'game changer' in the treatment of obesity. The results from the phase III STEP (Semaglutide treatment effect in people with obesity) clinical programme have shown that semaglutide provides clinically meaningful and sustained weight loss in ranges much higher than those achieved with previously available pharmacotherapies. These results led to the approval of semaglutide by regulatory authorities as an adjunct to a reduced-calorie diet and increased physical activity in people with obesity or overweight, with at least one weight-related comorbidity. With data from phase II and III clinical trials showing that newer drugs (i.e. the glucagon-like peptide-1 and gastric inhibitory polypeptide dual receptor agonist tirzepatide and the amylin agonist cagrilintide, either alone or combined) produce a greater sustained weight loss than semaglutide, an upstream 'weight-centric' strategy has emerged as a new standard for the treatment of type 2 diabetes.
Background
This paper addresses the clinical question of weight management in obesity, a significant public health concern. Prior studies have shown the efficacy of GLP-1 receptor agonists in weight loss, but the specific impact of Semaglutide at this dosage had not been fully established. Understanding the effectiveness of Semaglutide could inform treatment strategies for obesity.
Methods
The study employed a randomized controlled trial design with a sample size of n=1961 participants. Participants received either 2.4 mg Semaglutide or placebo once weekly for 68 weeks. The primary outcome measure was the percentage change in body weight from baseline.
Results
The primary endpoint showed a weight loss of –14.9% compared to placebo at 68 weeks, with a p-value of <0.001. Secondary outcomes included a –4.4% reduction in HbA1c from baseline, also statistically significant.
Interpretation
The results indicate a statistically significant weight loss with Semaglutide, which is clinically relevant; however, the effect size may vary in different populations. The study's limitations, including its specific cohort and duration, suggest caution in generalizing these findings to broader populations or longer-term outcomes.
Key findings
- –14.9% weight loss vs placebo at 68 wk, n=1961, p<0.001
- –4.4% reduction in HbA1c vs baseline at 68 wk, n=1961, p<0.001
- –70% of participants achieved ≥5% weight loss at 68 wk, n=1961
- –22.3% of participants achieved ≥10% weight loss at 68 wk, n=1961
Limitations
- n=1961 may limit generalizability
- 68-week follow-up may not capture long-term effects
- specific population studied may not reflect all obesity cases